Bavarian Nordic initiates Phase II trial in HIV infected individuals  

2005.07.28
Danish biopharmaceutical company Bavarian Nordic has initiated a Phase II trial to test the safety and immunogenicity of its smallpox vaccine Imvamune in HIV infected individuals

The Danish biopharmaceutical company Bavarian Nordic has initiated a Phase II trial to test the safety and immunogenicity of its smallpox vaccine Imvamune in HIV infected individuals. The study involves 150 people and is being conducted at 5 centres in the US. It is Bavarian Nordic's second clinical safety and efficiency study with Imvamune in HIV infected patients, and so far the studies are the only ones which are evaluating a safe smallpox vaccine in humans who cannot be vaccinated with traditional smallpox vaccines.

In addition, Bavarian Nordic has completed two trials with a recombinant MVA (Modified Vaccinia Ankara) based HIV vaccine in people with HIV, and have an ongoing Phase II trial with this vaccine. In these studies 52 HIV infected individuals were vaccinated with a dose up to five times higher than the smallpox vaccine Imvamune. The results so far have been very encouraging and have given important safety information. The news is reported by financial daily newspaper Børsen and on the Bavarian Nordic website.

Bavarian Nordic develops, produces and markets innovative vaccines to prevent and treat infectious diseases (smallpox and HIV), and cancer. Bavarian Nordic is one of the few companies in the world able to supply the growing demand for smallpox vaccines, in particular safe smallpox vaccines. The company has a combined global manufacturing capacity consisting of the build-up of its own production facility in Denmark, an international collaboration with GlaxoSmithKline, and an established partnership with vaccine producer, Impfstoffwerk Dessau-Tornau (IDT).

Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×